Literature DB >> 23085219

Acute N-methyl-D-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats.

I Feinstein1, M F Kritzer.   

Abstract

Schizophrenia is a complex constellation of positive, negative and cognitive symptoms. Acute administration of the non-competitive antagonist of the N-methyl-d-aspartate receptor (NMDAR) dizocilpine (MK801) in rats is one of few preclinical animal models of this disorder that has both face and/or construct validity for these multiple at-risk behavioral domains and predictive power for the efficacy of therapeutic drugs in treating them. This study asked whether and to what extent the rat NMDAR hypofunction model also embodies the sex differences that distinguish the symptoms of schizophrenia and their treatment. Thus, we compared the effects of acute MK801, with and without pretreatment with haloperidol or clozapine, on seven discrete spontaneous open-field activities in adult male and female rats. These analyses revealed that MK801 was more effective in stimulating ataxia and locomotion and inhibiting stationary behavior in females while more potently stimulating stereotypy and thigmotaxis and inhibiting rearing and grooming in males. Haloperidol and clozapine pretreatments had markedly different efficacies in terms of behaviors but strong similarities in their effectiveness in male and female subjects. These results bear intriguing relationships with the complex male/female differences that characterize the symptoms of schizophrenia and suggest possible applications for acute NMDAR hypofunction as a preclinical model for investigating the neurobiology that underlies them.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085219      PMCID: PMC3525798          DOI: 10.1016/j.neuroscience.2012.10.026

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  79 in total

Review 1.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

Review 2.  The role of the cerebellum in schizophrenia.

Authors:  Nancy C Andreasen; Ronald Pierson
Journal:  Biol Psychiatry       Date:  2008-04-08       Impact factor: 13.382

3.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze.

Authors:  R W Dunn; R Corbett; S Fielding
Journal:  Eur J Pharmacol       Date:  1989-10-04       Impact factor: 4.432

5.  Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol.

Authors:  Gwenaëlle Le Pen; Thérèse M Jay; Marie-Odile Krebs
Journal:  J Psychopharmacol       Date:  2010-11-18       Impact factor: 4.153

6.  Determination of serum and brain concentrations of neuroprotective and non-neuroprotective doses of MK-801.

Authors:  P H Schwartz; C G Wasterlain
Journal:  J Neurol Sci       Date:  1993-03       Impact factor: 3.181

7.  Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia.

Authors:  Young-Hoon Ko; Sung-Won Jung; Sook-Haeng Joe; Chang-Hyun Lee; Hyun-Gang Jung; In-Kwa Jung; Seung-Hyun Kim; Moon-Su Lee
Journal:  Psychoneuroendocrinology       Date:  2007-03-28       Impact factor: 4.905

8.  Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats.

Authors:  W F Gattaz; B Schummer; S Behrens
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 9.  Testosterone for schizophrenia.

Authors:  A Elias; A Kumar
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

10.  Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior.

Authors:  J B Becker; T E Robinson; K A Lorenz
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

View more
  11 in total

1.  Postnatal MK-801 treatment of female rats impairs acquisition of working memory, but not reference memory in an eight-arm radial maze; no beneficial effects of enriched environment.

Authors:  Masoumeh Nozari; Farshad Alizadeh Mansouri; Mohammad Shabani; Hojat Nozari; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2015-03-07       Impact factor: 4.530

Review 2.  Sex differences in brain-derived neurotrophic factor signaling and functions.

Authors:  Chi Bun Chan; Keqiang Ye
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

4.  Sex Differences Distinguish Intracortical Glutamate Receptor-Mediated Regulation of Extracellular Dopamine Levels in the Prefrontal Cortex of Adult Rats.

Authors:  M N Locklear; A B Cohen; A Jone; M F Kritzer
Journal:  Cereb Cortex       Date:  2014-09-26       Impact factor: 5.357

5.  Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.

Authors:  Masoumeh Nozari; Mohammad Shabani; Mahdieh Hadadi; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

Review 6.  Sex differences in the neurobiology of epilepsy: a preclinical perspective.

Authors:  Helen E Scharfman; Neil J MacLusky
Journal:  Neurobiol Dis       Date:  2014-07-21       Impact factor: 5.996

7.  MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia.

Authors:  Paul C Guest; Keiko Iwata; Takahiro A Kato; Johann Steiner; Andrea Schmitt; Christoph W Turck; Daniel Martins-de-Souza
Journal:  Front Cell Neurosci       Date:  2015-05-12       Impact factor: 5.505

8.  Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats.

Authors:  Kai Lei; Guo-Fang He; Cheng-Liang Zhang; Ya-Nan Liu; Juan Li; Guang-Zhao He; Xi-Ping Li; Xiu-Hua Ren; Dong Liu
Journal:  Exp Anim       Date:  2017-12-08

9.  Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action.

Authors:  Xingqin Zhou; Gangming Cai; Shishi Mao; Dong Xu; Xijie Xu; Rongjun Zhang; Zhiwen Yao
Journal:  BMC Psychiatry       Date:  2020-03-06       Impact factor: 3.630

10.  Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG.

Authors:  Kimberly M Holter; Alex D Lekander; Christina M LaValley; Elizabeth G Bedingham; Bethany E Pierce; L Paul Sands; Craig W Lindsley; Carrie K Jones; Robert W Gould
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.